30 active trials 14 recruiting 17 Phase 3 7 disease areas 9 changes in 30 days
| Phase 1 | 4 | |
| Phase 1/2 | 3 | |
| Phase 2 | 4 | |
| Phase 2/3 | 2 | |
| Phase 3 | 15 | |
| Phase 4 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07538570 | Evaluation of Pain Treatment After Total Knee Arthroplasty | Pain | Recruiting | 2026-08-18 |
| Phase 3 | ||||
| NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic… | Diabetic Peripheral Neuropathic Pain | Recruiting | 2026-07-20 |
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Diabetes Mellitus, Type 1 | Recruiting | 2026-06-30 |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic… | Diabetic Peripheral Neuropathic Pain | Recruiting | 2026-06-15 |
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With… | Beta-Thalassemia | Recruiting | 2026-03-23 |
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1… | Type 1 Diabetes | Recruiting | 2026-03-23 |
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | Beta-Thalassemia | Enrolling by Invitation | 2026-08-11 |
| NCT05331183 | Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and… | Cystic Fibrosis | Active, Not Recruiting | 2026-08-11 |
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Cystic Fibrosis | Active, Not Recruiting | 2026-07-21 |
| NCT05329649 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle… | Sickle Cell Disease | Active, Not Recruiting | 2026-07-01 |
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With… | Beta-Thalassemia | Active, Not Recruiting | 2026-07-01 |
| NCT06460506 | Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis… | Cystic Fibrosis | Active, Not Recruiting | 2026-06-05 |
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1… | Cystic Fibrosis | Active, Not Recruiting | 2026-05-28 |
| NCT06696443 | Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants… | Diabetic Peripheral Neuropathic Pain | Active, Not Recruiting | 2026-05-18 |
| NCT06564142 | Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) | Immunoglobulin A Nephropathy | Active, Not Recruiting | 2026-05-15 |
| NCT05844449 | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in… | Cystic Fibrosis | Enrolling by Invitation | 2026-04-29 |
| Phase 2/3 | ||||
| NCT05312879 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With… | Proteinuric Kidney Disease | Recruiting | 2026-08-26 |
| NCT07204275 | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With… | Primary Membranous Nephropathy | Recruiting | 2026-08-03 |
| Phase 2 | ||||
| NCT07501702 | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized | Recruiting | 2026-08-03 |
| NCT06619860 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral… | Diabetic Peripheral Neuropathic Pain | Recruiting | 2026-06-01 |
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene… | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Active, Not Recruiting | 2026-08-11 |
| NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic… | Myotonic Dystrophy Type 1 (DM1) | Enrolling by Invitation | 2026-08-10 |
| Phase 1/2 | ||||
| NCT06185764 | A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | Myotonic Dystrophy Type 1 (DM1) | Active, Not Recruiting | 2026-08-20 |
| NCT05791201 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | Type 1 Diabetes | Active, Not Recruiting | 2026-06-04 |
| NCT05668741 | A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) | Cystic Fibrosis | Active, Not Recruiting | 2026-05-22 |
Cystic Fibrosis (8) · Sickle Cell Disease (3) · Thalassemia (3) · Diabetes (3) · Chronic Kidney Disease (3) · Type 1 Diabetes (2) · Myasthenia Gravis (1)